Takayasu Arteritis Clinical Trial
Official title:
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
Takayasu arteritis (TA) is a vasculitis of unknown origin, resulting in progressive thickening and stenosis of large and medium arteries (the aorta and its major branches, and the pulmonary arteries). First line therapy of TA consists of high dose corticosteroids (CS). Between 20 and 50% of cases respond to CS alone, with subsequent resolution of symptoms and stabilization of vascular abnormalities. Although second-line agents (methotrexate, azathioprine, mercaptopurine, mycophenolate mofetil) may result in initial remission, relapses remain common when prednisone is tapered. Thus, 50% of CS-resistant or relapsing TA patients may achieve sustained remission with the addition of methotrexate. During the last decade, biologics such as anti-tumor necrosis factor alpha (anti-TNFα) and anti-interleukin-6 (anti-IL-6) have been used as third-line treatment in refractory or relapsing TA. Almost 90% of CS-methotrexate resistant TA cases responded to infliximab, an anti-TNFα, and sustained remission was obtained in 37 to 76% of the cases. Tocilizumab, an anti-IL-6 has given similar results with 68% of sustained remission in refractory TA. Irrespective of classical cardiovascular risk factors, the systemic inflammation and CS use play a pivotal role in the occurrence of cardiovascular thrombotic events (CVEs). As CVEs overlap with TA complications it is primordial to drastically taper CS in that vasculitis. We therefore hypothesize that Infliximab or Tocilizumab can achieve a remission in more than 70% of refractory/relapsing TA cases to CS associated to a second-line agent. INTOReTAK, first randomized prospective study in TA, has an original design testing Infliximab and Tocilizumab propensity to achieve over 70% of sustained remission in refractory/relapsing TA and evaluating jointly the 2 arms. The primary objective of this study is to obtain, by arm, ≥ 70% of patients at 6 months after randomization with prednisone ≤ 0.1mg/kg per day and inactive disease (NIH score ≤ 1) during the last 3 months.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04882072 -
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
|
Phase 3 | |
Completed |
NCT03750929 -
Aerobic Capacity and Strength Exercise in Takayasu's Arteritis
|
N/A | |
Recruiting |
NCT04137614 -
Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis
|
N/A | |
Recruiting |
NCT02967068 -
VCRC Tissue Repository
|
||
Recruiting |
NCT05102448 -
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
|
Phase 4 | |
Recruiting |
NCT03893136 -
The Registry Study of Takayasu Arteritis in East China
|
||
Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
Completed |
NCT03096275 -
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
|
Phase 3 | |
Recruiting |
NCT04299971 -
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
|
Phase 4 | |
Recruiting |
NCT04300686 -
A Pilot Study in Severe Patients With Takayasu Arteritis.
|
Phase 4 | |
Recruiting |
NCT03192878 -
Infliximab Biosimilar in Takayasu's Arteritis
|
N/A | |
Active, not recruiting |
NCT04071691 -
PET Imaging of Giant Cell and Takayasu Arteritis
|
||
Recruiting |
NCT05904301 -
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
|
||
Completed |
NCT02101333 -
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
|
Phase 3 | |
Not yet recruiting |
NCT03550781 -
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05168475 -
Biologics in Refractory Vasculitis
|
Phase 2 | |
Completed |
NCT03956394 -
Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging
|
N/A | |
Recruiting |
NCT05151848 -
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
|
Phase 4 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Completed |
NCT02925351 -
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
|
Early Phase 1 |